Charles F. Reynolds, III, M.D.
Name, Degree: Charles F. Reynolds III, M.D.
Role(s) in Task Force and Work Group: Chair, Sleep-Wake Disorders Work Group
Institutional Affiliation(s): University of Pittsburgh School of Medicine
City, State: Pittsburgh, PA
Biographical Sketch:
Chair, Sleep Disorders Work Group
Member, DSM-V Task Force
Professor of Geriatric Psychiatry,
Professor of Psychiatry, Neurology, and Neuroscience
University of Pittsburgh
Dr. Reynolds directs the National Institute of Mental Health–sponsored Advanced Center for Interventions and Services Research in Late-Life Mood Disorders and the John A. Hartford Center of Excellence in Geriatric Psychiatry at the University of Pittsburgh. The themes of his research program encompass the prevention of depression in old age, treatment algorithms for difficult-to-treat mood disorders in later life, and dissemination and implementation of evidence-based practices for depression treatment in underserved populations.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
American Association for Geriatric Psychiatry |
2005-present |
President-elect |
|
American Foundation for Suicide Prevention |
2006-present |
Vice President and member, Scientific Advisory Board |
The two tables below represent Dr. Reynolds’ disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Reynolds has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Glaxo Smith Kline |
1999-2006 |
3 |
|
Forest Laboratories |
2004-present |
3 |
|
Pfizer |
2004-present |
3 |
|
Eli Lilly |
2005-present |
3 |
|
BMS |
2005-present |
3 |
|
American Journal of Geriatric Psychiatry: Associate Editor |
2003-present |
4 (stipend) |
|
Wyeth |
2006-2007 |
3 |
|
John D. Hartford Foundation |
2005-2007 |
3 (Foundation) |
Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Forest Laboratories |
2008 |
3 |
|
Pfizer |
2008 |
3 |
|
BMS |
2008 |
3 |
|
Wyeth |
2008 |
3 |
|
Lilly |
2008 |
3 |
|
GSK |
2008 |
3 |
| John D. Hartford Foundation |
2008 |
3 (Foundation) |
| American Journal of Geriatric Psychiatry |
2008 |
10 (stipend) |